Mantle Cell Lymphoma - Pipeline Review, H2 2012

Global Markets Direct, July 2012, Pages: 342

Mantle Cell Lymphoma – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Mantle Cell Lymphoma - Pipeline Review, H2 2012', provides an overview of the Mantle Cell Lymphoma therapeutic pipeline. This report provides information on the therapeutic development for Mantle Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma. 'Mantle Cell Lymphoma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Mantle Cell Lymphoma.
- A review of the Mantle Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Mantle Cell Lymphoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Mantle Cell Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Mantle Cell Lymphoma pipeline depth and focus of Mantle Cell Lymphoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Mantle Cell Lymphoma Therapeutic Products under Development, Key Players in Mantle Cell Lymphoma Therapeutics, Mantle Cell Lymphoma Pipeline Overview, Mantle Cell Lymphoma Pipeline, Mantle Cell Lymphoma Pipeline Assessment

2
List of Tables 8
List of Figures 9
Introduction 10
REPORT COVERAGE 10
Mantle Cell Lymphoma Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Mantle Cell Lymphoma 12
Mantle Cell Lymphoma Therapeutics under Development by Companies 14
Mantle Cell Lymphoma Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 22
Comparative Analysis 22
Mid Clinical Stage Products 23
Comparative Analysis 23
Early Clinical Stage Products 24
Comparative Analysis 24
Discovery and Pre-Clinical Stage Products 25
Comparative Analysis 25
Mantle Cell Lymphoma Therapeutics – Products under Development by Companies 26
Mantle Cell Lymphoma Therapeutics – Products under Investigation by Universities/Institutes 28
Companies Involved in Mantle Cell Lymphoma Therapeutics Development 35
F. Hoffmann-La Roche Ltd. 35
Abbott Laboratories 36
Amgen Inc. 37
Sanofi-Aventis 38
GlaxoSmithKline plc 39
Gilead Sciences, Inc. 40
Lentigen Corporation 41
Takeda Pharmaceutical Company Limited 42
Piramal Healthcare Limited 43
Millennium Pharmaceuticals, Inc. 44
Novartis AG 45
BioMarin Pharmaceutical Inc. 46
Cephalon, Inc. 47
Pfizer Inc. 48
Celgene Corporation 49
Onyx Pharmaceuticals, Inc. 50
Celldex Therapeutics, Inc. 51
Accentia Biopharmaceuticals, Inc. 52
Telik, Inc. 53
Pharmacyclics, Inc. 54
Memgen, LLC. 55
Semafore Pharmaceuticals, Inc. 56
Onconova Therapeutics, Inc 57
Cylene Pharmaceuticals, Inc. 58
Astellas Pharma GmbH 59
Cancer Therapeutics CRC Pty Ltd 60
Advancell 61
Mantle Cell Lymphoma – Therapeutics Assessment 62
Assessment by Monotherapy Products 62
Assessment by Combination Products 63
Assessment by Route of Administration 64
Assessment by Molecule Type 66
Drug Profiles 69
ABT-263 - Drug Profile 69
CDX-1127 - Drug Profile 71
Acadra - Drug Profile 72
PCI-32765 - Drug Profile 73
PCI-24781 - Drug Profile 75
SAR245409 - Drug Profile 77
LBH589 - Drug Profile 79
BiovaxID - Drug Profile 82
Velcade - Drug Profile 84
ONX 0912 - Drug Profile 85
Bendamustine Hydrochloride - Drug Profile 86
ISF35 Vaccine - Drug Profile 88
Telcyta - Drug Profile 89
SF1126 - Drug Profile 91
ON 013105 - Drug Profile 93
P276 - Drug Profile 94
Rituximab + Lenalidomide + Bortezomib - Drug Profile 96
Clofarabine - Drug Profile 98
RAD001 + Velcade - Drug Profile 99
Rituximab - Drug Profile 101
Velcade + Rituximab - Drug Profile 102
Lenalidomide + Dexamethasone - Drug Profile 103
Velcade + Bexxar - Drug Profile 106
Bendamustine + Rituximab - Drug Profile 108
Bortezomib + Vorinostat - Drug Profile 109
Bendamustine + Rituximab - Drug Profile 110
Therapeutic Allogeneic Lymphocytes - Drug Profile 111
RAD001 - Drug Profile 112
LG740 - Drug Profile 113
Everolimus - Drug Profile 114
PD-0332991 - Drug Profile 115
CCI-779 + Rituximab - Drug Profile 117
Velcade + RCHOP - Drug Profile 118
Inotuzumab Ozogamicin + Rituxan - Drug Profile 120
Treanda + Rituxan - Drug Profile 122
GS 1101 + Bendamustine + Rituximab - Drug Profile 124
GS 1101 + Bendamustine - Drug Profile 126
GS-1101 + Rituximab - Drug Profile 127
Revlimid - Drug Profile 129
Fludarbine + Mitoxantrone + Rituxan + Zevalin - Drug Profile 131
Rituximab + Cladribine + Temsirolimus - Drug Profile 133
Iodine-131 Anti-B1 Antibody + CHOP - Drug Profile 135
Bortezomib + Gemcitabine - Drug Profile 138
Alvocidib - Drug Profile 143
Rituximab - Drug Profile 144
Bortezomib + Revlimid - Drug Profile 146
Velcade + CHOP-R - Drug Profile 150
Rituximab + Bendamustine + Cytarabine - Drug Profile 152
VELCADE-R-CAP - Drug Profile 156
Velcade + Rituximab + Cyclophosphamide - Drug Profile 158
Rituximab + Cyclophosphamide + Fludarabine - Drug Profile 161
Rituxan - Drug Profile 167
Gemcitabine - Drug Profile 168
RAD001 + Revlimid - Drug Profile 169
Lenalidomide + Bendamustine + Rituximab - Drug Profile 170
HMR 1275 - Drug Profile 172
R-CHOP-V - Drug Profile 173
Rituximab + Carboplatin + Etoposide + Ifosfamide + Vorinostat - Drug Profile 175
Cyclophosphamide + Etoposide + Rituximab + Radioimmunotherapy - Drug Profile 177
Aldesleukin + Cyclophosphamide + Therapeutic Autologous Lymphocytes - Drug Profile 179
PD 0332991 + Bortezomib - Drug Profile 181
Lenalidomide + Dexametasone - Drug Profile 182
Treanda + Carboplatin + Rituximab + Etoposide - Drug Profile 185
Nelfinavir + Bortezomib - Drug Profile 189
CHOP + Bortezomib - Drug Profile 190
R-CMD - Drug Profile 196
Fludarabine + Rituximab - Drug Profile 200
Lenalidomide + R-CHOP - Drug Profile 206
Temsirolimus + Rituximab + Bendamustine - Drug Profile 210
Pegfilgrastim + Rituximab + Cyclophosphamide - Drug Profile 215
Allogeneic Stem Cell Transplantation - Drug Profile 219
Rituximab + Cladribine + Vorinostat - Drug Profile 221
Rituximab + Velcade + Cladribine - Drug Profile 222
Rituximab + Bortezomib + Cyclophosphamide + Prednisone - Drug Profile 223
Rituximab + CHOP + Yttrium-90 Ibritumomab Tiuxetan + Radiation Therapy - Drug Profile 225
Zevalin + BEAM + Autologous Stem Cell Transplantation - Drug Profile 227
CpG-MCL Vaccine + Autologous Peripheral Blood Stem Cell Transplantation - Drug Profile 235
Cytarabine + Doxorubicin - Drug Profile 236
Rituximab + Cyclophosphamide + Bortezomib + Dexamethasone - Drug Profile 252
Fludarabine + Mitoxantrone + Rituximab + Zevalin - Drug Profile 253
Velcade + Rituximab - Drug Profile 254
Dexamethasone + Arzerra + Treanda - Drug Profile 258
CX-5461 - Drug Profile 260
BMN 673 - Drug Profile 261
Tipifarnib - Drug Profile 263
Velcade + Rituxan - Drug Profile 264
Zevalin + Rituxan - Drug Profile 265
AMG 319 - Drug Profile 269
Bortezomib + Fludarabine + Cyclophosphamide - Drug Profile 270
Bendamustine + Rituximab - Drug Profile 272
Bendamustine - Drug Profile 273
Temsirolimus + Rituximab + Bortezomib + Dexamethasone - Drug Profile 274
Bendamustine + Rituximab - Drug Profile 276
LBH589 - Drug Profile 277
MabThera + Fludarabine + Cyclophosphamide + Mitoxantrone - Drug Profile 279
Ofatumumab + Bortezomib - Drug Profile 281
GS 1101 + Ofatumumab - Drug Profile 282
GS 1101 + Fludarabine - Drug Profile 283
SAR245409 + Rituximab - Drug Profile 284
SAR245409 + Bendamustine + Rituximab - Drug Profile 285
SAR245409 + Bendamustine - Drug Profile 286
Rituximab + Bendamustine + Cyclophosphamide + Stem Cell Transplantation - Drug Profile 287
Ofatumumab + Bendamustine - Drug Profile 291
Ofatumumab - Drug Profile 292
Drug Targeting PRMT5 - Drug Profile 293
Mantle Cell Lymphoma Therapeutics – Drug Profile Updates 294
Mantle Cell Lymphoma Therapeutics – Discontinued Products 317
Mantle Cell Lymphoma Therapeutics - Dormant Products 318
Mantle Cell Lymphoma – Product Development Milestones 322
Featured News & Press Releases 322
Appendix 332
Methodology 332
Coverage 332
Secondary Research 332
Primary Research 332
Expert Panel Validation 332
Contact Us 333
Disclaimer 333

List of Tables
Number of Products Under Development for Mantle Cell Lymphoma, H2 2012 21
Products under Development for Mantle Cell Lymphoma – Comparative Analysis, H2 2012 22
Number of Products under Development by Companies, H2 2012 24
Number of Products under Development by Companies, H2 2012 (Contd..1) 25
Number of Products under Investigation by Universities/Institutes, H2 2012 27
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 28
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 29
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 30
Comparative Analysis by Late Stage Development, H2 2012 31
Comparative Analysis by Mid Clinical Stage Development, H2 2012 32
Comparative Analysis by Early Clinical Stage Development, H2 2012 33
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 34
Products under Development by Companies, H2 2012 35
Products under Development by Companies, H2 2012 (Contd..1) 36
Products under Investigation by Universities/Institutes, H2 2012 37
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 38
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 39
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 40
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 41
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 42
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 43
F. Hoffmann-La Roche Ltd., H2 2012 44
Abbott Laboratories, H2 2012 45
Amgen Inc., H2 2012 46
Sanofi-Aventis, H2 2012 47
GlaxoSmithKline plc, H2 2012 48
Gilead Sciences, Inc., H2 2012 49
Lentigen Corporation, H2 2012 50
Takeda Pharmaceutical Company Limited, H2 2012 51
Piramal Healthcare Limited, H2 2012 52
Millennium Pharmaceuticals, Inc., H2 2012 53
Novartis AG, H2 2012 54
BioMarin Pharmaceutical Inc., H2 2012 55
Cephalon, Inc., H2 2012 56
Pfizer Inc., H2 2012 57
Celgene Corporation, H2 2012 58
Onyx Pharmaceuticals, Inc., H2 2012 59
Celldex Therapeutics, Inc., H2 2012 60
Accentia Biopharmaceuticals, Inc., H2 2012 61
Telik, Inc., H2 2012 62
Pharmacyclics, Inc., H2 2012 63
Memgen, LLC., H2 2012 64
Semafore Pharmaceuticals, Inc., H2 2012 65
Onconova Therapeutics, Inc, H2 2012 66
Cylene Pharmaceuticals, Inc., H2 2012 67
Astellas Pharma GmbH, H2 2012 68
Cancer Therapeutics CRC Pty Ltd, H2 2012 69
Advancell, H2 2012 70
Assessment by Monotherapy Products, H2 2012 71
Assessment by Combination Products, H2 2012 72
Assessment by Stage and Route of Administration, H2 2012 74
Assessment by Stage and Molecule Type, H2 2012 77
Mantle Cell Lymphoma Therapeutics – Drug Profile Updates 303
Mantle Cell Lymphoma Therapeutics – Discontinued Products 326
Mantle Cell Lymphoma Therapeutics – Dormant Products 327
Mantle Cell Lymphoma Therapeutics – Dormant Products (Contd..1) 328
Mantle Cell Lymphoma Therapeutics – Dormant Products (Contd..2) 329
Mantle Cell Lymphoma Therapeutics – Dormant Products (Contd..3) 330

List of Figures
Number of Products under Development for Mantle Cell Lymphoma, H2 2012 21
Products under Development for Mantle Cell Lymphoma – Comparative Analysis, H2 2012 22
Products under Development by Companies, H2 2012 23
Products under Investigation by Universities/Institutes, H2 2012 26
Late Stage Products, H2 2012 31
Mid Clinical Stage Products, H2 2012 32
Early Clinical Stage Products, H2 2012 33
Discovery and Pre-Clinical Stage Products, H2 2012 34
Assessment by Monotherapy Products, H2 2012 71
Assessment by Combination Products, H2 2012 72
Assessment by Route of Administration, H2 2012 73
Assessment by Stage and Route of Administration, H2 2012 74
Assessment by Molecule Type, H2 2012 75
Assessment by Stage and Molecule Type, H2 2012 76

Customers who bought this item also bought

• Lymphoma - Pipeline Review, H2 2012
• Non-Hodgkin Lymphoma - Pipeline Review, H2 2012
• Brain Cancer - Pipeline Review, H2 2012
• Anemia - Pipeline Review, H2 2012
• Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy - Pipeline Review, H2 2012
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2012
• Cytopenia - Pipeline Review, H2 2012
• Myeloproliferative Disorders - Pipeline Review, H2 2012
• Systemic Lupus Erythematosus - Pipeline Review, H2 2012
• Pulmonary Fibrosis - Pipeline Review, H2 2012